



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/028,245	12/18/2001	Nigel Dunn-Coleman	GC700	2138

7590 02/16/2006

VICTORIA L. BOYD
Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94034-1013

EXAMINER

RAO, MANJUNATH N

ART UNIT PAPER NUMBER

1652

DATE MAILED: 02/16/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Supplemental
Notice of Allowability**

Application No.

10/028,245

Examiner

Manjunath N. Rao, Ph.D.

Applicant(s)

DUNN-COLEMAN ET AL.

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the amendment filed on 10-24-05.
2. ☒ The allowed claim(s) is/are 2,4-17,19,20,22-24 and 26.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

DETAILED ACTION

Claims 2, 4-17, 19-20, 22-24, 26 are currently pending and are present for examination.

Applicants' amendments and arguments filed on 10-24-05, have been fully considered and are deemed to be persuasive to overcome the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Drawings

Drawings submitted in this application are accepted by the Examiner for examination purposes only.

Information Disclosure Statement

The information disclosure statement filed 8-10-05 fails to comply with 37 CFR 1.97(d) because it lacks a statement as specified in 37 CFR 1.97(e) (applicants have failed to check the appropriate box). It has been placed in the application file, but the information referred to therein has not been considered.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Victoria Boyd on 2-14-06.

Art Unit: 1652

The application has been amended as follows:

In the claims:

- A) In claim 2, line 1, delete “an isolated” and replace with “A”.
- B) In claim 2, line 1, insert the phrase “isolated from a fungal source” after the word “polynucleotide”.
- C) In claim 2, line 1, delete the word “fungal”.
- D) In claim 2, line 4, delete “complementary” and replace with “a full length complement”.
- E) In claim 2, line 6, delete the phrase “presented in SEQ ID NOs:3 and 2”.
- F) In claim 2, line 6, insert the phrase “comprising SEQ ID NOs:3 and 2” after the word “Figure 2”.
- G) In claim 2, line 10, delete “complementary” and replace with “a full length complement”.
- H) In claim 2, line 12, delete the phrase “presented in SEQ ID NOs:3 and 2”.
- I) In claim 2, line 12, insert the phrase “comprising SEQ ID NOs:3 and 2” after the word “Figure 2”.
- J) In claim 2, line 13, delete “complementary” and replace with “a full length complement”.
- K) In claim 2, line 14-15, delete the phrase “presented in SEQ ID NOs:3 and 2”.
- L) In claim 2, line 15, insert the phrase “comprising SEQ ID NOs:3 and 2” after the word “Figure 2”.
- M) In claim 2, line 16, delete “complementary” and replace with “a full length complement”.
- N) In claim 2, line 18, delete the phrase “presented as”.
- O) In claim 2, line 19, delete “complementary” and replace with “a full length complement”.
- P) In claim 2, line 20, delete the phrase “presented as”.

Art Unit: 1652

- Q) In claim 2, line 22, delete the phrase “presented as”.
- R) In claim 2, line 22, insert the phrase “full length” after the word “the”.
- S) In claim 4, line 2, delete the phrase “presented as” without any prejudice.
- T) In claim 4, line 2, delete the phrase “or a fragment thereof”
- U) In claim 8, line 3, delete the phrase “presented in” without any prejudice.
- V) In claim 8, lines 4-5, delete the phrase “being capable of hybridizing to a probe designed to hybridize with the nucleotide sequence disclosed in SEQ ID NO:1 under conditions of high stringency of (iii)” without any prejudice.
- W) In claim 8, line 5, delete the phrase “being complementary” and replace with “being a full length complement”.
- X) In claim 8, line 6, delete the first recitation of “a” and replace with “the”.
- Y) In claim 8, line 7, delete the phrase “presented in”.
- Z) In claim 11, delete the phrase “A host cell” and replace with “An isolated host cell”.
- AA) In claim 12, delete the phrase “A host cell” and replace with “An isolated host cell”.
- BB) In claim 15, delete the phrase “A recombinant host cell” and replace with “An isolated recombinant host cell”.
- CC) In claim 19, line 3, delete the phrase “a host cell” and replace with “an isolated host cell”.
- DD) In claim 22, line 1, delete the phrase “A recombinant host cell” and replace with “An isolated recombinant host cell”.
- EE) In claim 22, line 2, delete the phrase “presented in”.
- FF) In claim 23, line 2, delete the phrase “presented as”.
- GG) In claim 26, line 4, delete the word “a” and replace with “the”.

Art Unit: 1652

HH) In claim 26 line 8, delete the second recitation of the word “chimeric” and replace with “heterologous”.

Allowable Subject Matter

Claims 2, 4-17, 19-20, 22-24, 26 are allowed.

The following is an examiner’s statement of reasons for allowance: Following a diligent search it was determined that the prior art neither teaches nor suggests a polynucleotide encoding a polypeptide with endoglucanase activity as claimed in claims 2, 4-17, 19-20, 22-24, 26.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.”

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Manjunath N. Rao, Ph.D. whose telephone number is 571-272-0939. The Examiner can normally be reached on 7.00 a.m. to 3.30 p.m. If attempts to reach the examiner by telephone are unsuccessful, the Examiner’s supervisor, Ponnathapura Achutamurthy can be reached on 571-272-0928. The fax phone numbers for the organization where this application or proceeding is assigned is 571-273-8300 for regular communications and for After Final communications.

Art Unit: 1652

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

A handwritten signature in black ink, appearing to read "Manjunath N. Rao". The signature is stylized with a large, looping initial "M" and a trailing flourish.

Manjunath N. Rao, Ph.D.
Primary Examiner
Art Unit 1652

February 14th, 2006